These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
790 related articles for article (PubMed ID: 29890998)
1. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. Yang JM; Jang JY; Jeon YK; Paik JH J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998 [TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
3. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453 [TBL] [Abstract][Full Text] [Related]
4. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967 [TBL] [Abstract][Full Text] [Related]
5. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893 [TBL] [Abstract][Full Text] [Related]
6. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Lanic H; Mareschal S; Mechken F; Picquenot JM; Cornic M; Maingonnat C; Bertrand P; Clatot F; Bohers E; Stamatoullas A; Leprêtre S; Rainville V; Ruminy P; Bastard C; Tilly H; Becker S; Vera P; Jardin F Leuk Lymphoma; 2012 Jan; 53(1):34-42. PubMed ID: 21806349 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394 [TBL] [Abstract][Full Text] [Related]
8. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767 [TBL] [Abstract][Full Text] [Related]
9. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population. Chen W; Wang H; Chen H; Liu S; Lu H; Kong D; Huang X; Kong Q; Lu Z Eur J Haematol; 2014; 92(5):407-12. PubMed ID: 24400911 [TBL] [Abstract][Full Text] [Related]
11. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608 [TBL] [Abstract][Full Text] [Related]
12. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464 [TBL] [Abstract][Full Text] [Related]
13. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729 [TBL] [Abstract][Full Text] [Related]
14. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma. Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390 [TBL] [Abstract][Full Text] [Related]
15. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment]. Cao QW; Li HY; Yao XX; Wang JF Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1010-4. PubMed ID: 23363792 [TBL] [Abstract][Full Text] [Related]
16. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Slack GW; Steidl C; Sehn LH; Gascoyne RD Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752 [TBL] [Abstract][Full Text] [Related]
17. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757 [TBL] [Abstract][Full Text] [Related]
18. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970 [TBL] [Abstract][Full Text] [Related]
19. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992 [TBL] [Abstract][Full Text] [Related]
20. Tissue microarray in a subset of South African patients with DLBCL. Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]